KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EBT (2019 - 2025)

GoodRx Holdings' EBT history spans 7 years, with the latest figure at $14.2 million for Q4 2025.

  • For Q4 2025, EBT rose 24.4% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $56.5 million, up 79.71%, while the annual FY2025 figure was $56.5 million, 79.71% up from the prior year.
  • EBT for Q4 2025 was $14.2 million at GoodRx Holdings, up from $6.1 million in the prior quarter.
  • Across five years, EBT topped out at $19.6 million in Q2 2025 and bottomed at -$46.6 million in Q3 2023.
  • The 5-year median for EBT is $4.7 million (2021), against an average of -$49100.0.
  • The largest annual shift saw EBT plummeted 2154.52% in 2022 before it skyrocketed 5588.74% in 2025.
  • A 5-year view of EBT shows it stood at $5.9 million in 2021, then tumbled by 180.83% to -$4.7 million in 2022, then plummeted by 419.18% to -$24.6 million in 2023, then surged by 146.31% to $11.4 million in 2024, then grew by 24.4% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's EBT are $14.2 million (Q4 2025), $6.1 million (Q3 2025), and $19.6 million (Q2 2025).